- In April 2024, Beckman Coulter, Inc. (U.S.), a leading player in clinical diagnostics, launched a next-generation chemiluminescence analyzer designed to enhance throughput and reduce turnaround times for high-volume laboratories. This development strengthens the company's commitment to advancing immunoassay technology and addressing the growing demand for faster, more accurate diagnostic solutions in hospital and reference labs
- In March 2024, Siemens Healthineers AG (Germany) introduced an upgraded version of its Atellica Solution CLA platform, featuring expanded test menu capabilities and improved integration with laboratory automation systems. This enhancement is aimed at improving workflow efficiency and result accuracy, particularly in multi-disciplinary diagnostic centers across Europe and North America
- In February 2024, DiaSorin S.p.A. (Italy) announced a strategic collaboration with a U.S.-based biotech firm to co-develop advanced chemiluminescent assays for infectious disease detection. This partnership is set to accelerate innovation in the CLA space, enabling the rapid introduction of new test panels for emerging pathogens and high-demand screening programs
- In January 2024, F. Hoffmann-La Roche Ltd (Switzerland) unveiled a novel CLA-based assay for early cancer detection at the MedLab Middle East conference. Designed for use with Roche’s cobas e analyzers, the new assay delivers enhanced sensitivity and faster results, reflecting the company’s continued investment in oncology diagnostics and precision medicine
- In December 2023, QuidelOrtho Corporation (U.S.) expanded its global footprint by launching its chemiluminescence analyzer systems in Southeast Asia. The move targets emerging markets with rising healthcare infrastructure needs, and includes local partnerships for training, installation, and support—reinforcing the brand’s commitment to accessibility and operational excellence in diagnostics
